German drug discovery and development company Evotec has entered into a multi-year master research collaboration and option and license agreement with US pharma giant Pfizer. 11 July 2024
UK-headquartered clinical-stage company OKYO Pharma’s today shared promising new categorical data analyses from the recent OK-101 Phase II trial in dry eye disease (DED) patients. 10 July 2024
Immunic, a US biotech developing a pipeline of orally-administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has appointed experienced biopharma executive Jason Tardio as chief operating officer and president. 9 July 2024
Stalicla, a privately-held Swiss biotech developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders such as autism spectrum disorder, has named Purnanand Sarma as chair of its board of directors. 9 July 2024
Boston, USA-based clinical-stage biopharma company HilleVax saw its shares plummet more than 88% to $1.64 by lose of trading on Monday as it pulled the plug on its lead vaccine candidate in infants. 9 July 2024
Florida, USA-based Ligand Pharmaceuticals today announced that it has entered into a definitive agreement to acquire privately-held Austrian company Aperion Biologics. 8 July 2024
Kineta saw its shares rise almost 30% to $0.79 in pre-market activity, on news that it has entered into an exclusivity and right of first offer agreement with TuHURA Biosciences. 8 July 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, has announced the appointment of Paul Carter as chair of the board of directors. 8 July 2024
Ascentage Pharma yesterday announced that olverembatinib has been approved by the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region (SAR) of China. 8 July 2024
China’s National Medical Products Administration (NMPA) has approved Xpovio (selinexor), from Antengene Corp as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). 8 July 2024
Myricx Bio, a UK biotech focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), has announced the closing of its s
Series A financing raising £90 million ($114 million). 8 July 2024
New Jersey, USA-based biopharma firm Insmed (Nasdaq: INSM) has revealed additional positive outcomes from its Phase III ASPEN study of brensocatib. 4 July 2024
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024